Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  SIX SWISS EXCHANGE AG  >  Roche Holding Ltd.       CH0012032048

ROCHE HOLDING LTD.
Mes dernières consult.
Most popular
Report
SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
Latest news on ROCHE HOLDING LTD.
10/20 ROCHE : 66-- Notice of Intent-Sole Source IDIQ Roche laboratory supplies
10/20 INOVIO PHARMACEUTICALS : Begins Phase 1b/2 Cancer Efficacy Trial Combining Its T..
10/19 PTC THERAPEUTICS : Spinal Muscular Atrophy Program Advances into Pivotal Study i..
10/19 FOUNDATION MEDICINE : Appoints Tom Civik as Chief Commercial Officer
10/19DJEuropean Corporate Roundup for Thursday
10/19DJEuropean Corporate Roundup for Thursday
10/19 ROCHE : Swiss biotech group Roche sees 5 pct rise in 9-month sales
10/19DJROCHE : 3Q Sales Increase on Strong Performance of Recently Launched Drugs
10/19 ROCHE : reports strong sales growth in the first nine months of 2017
10/19 ROCHE : Partitions
10/18 FTSE rises to record close, blue-chips shrug off Reckitt blip
10/18 ROCHE : $6.4 Million Federal Contract Awarded to Roche Diagnostics
10/18 ROCHE : Warp Drive and Roche collaborate to develop new classes of antibiotics
10/17 HALOZYME THERAPEUTICS : HALO) Commences Clinical Trial Of PEGPH20 With Anti-PDL1..
10/17 ROCHE : kicks antibiotic development into Warp Drive
10/17 HALOZYME THERAPEUTICS : Initiates Clinical Trial Of PEGPH20 With Anti-PDL1 Immun..
10/17 ROCHE : Cambridge biotech signs deal to take on superbugs
10/17 FOUNDATION MEDICINE : Study Shows Genomic Profiling Can Help Improve Treatment o..
10/16ROCHE HOLDING LTD. : quaterly sales release
10/16 ROCHE : J-- Nexes Strainer (Lab) - Annual Service/Support (Lab) | (Roche Diagnos..
10/16 ROCHE : to present new OCREVUS (ocrelizumab) efficacy and safety data in relapsi..
10/16 GENENTECH : to Present New OCREVUS (Ocrelizumab) Efficacy & Safety Data in Relap..
10/14 ROCHE : Value of conducting clinical trials in Saudi Arabia rising
10/13 ROCHE : CHMP recommends EU approval of Roche's Alecensa (alectinib) as a first-l..
10/13 ROCHE : Ventana Stain Systems Reagent/Chemical Solutions One-year Requirements C..
10/13DJROCHE : Gets CHMP Recommendation for Lung Cancer Treatment Alecensa
10/13 NOVARTIS AG (ADR)(NYSE : NVS) Says It Will Not Sell Its Stake In Roche
10/13 ROCHE : CHMP recommends EU approval of Roche’s Alecensa (alectinib) as a f..
10/13 World Molecular Diagnostics Market is Projected to Reach More Than US$ 30 Bil..
10/13 ROCHE : $212,860 Federal Contract Awarded to Roche Diagnostics
10/12 FOUNDATION MEDICINE : Receives Approval from the State of New York for its Found..
10/12 FOUNDATION MEDICINE : Researchers at Foundation Medicine Inc. Have Reported New ..
10/12 CHUGAI PHARMACEUTICAL : New Breast Cancer Study Findings Reported from Chugai Ph..
10/12 CHUGAI PHARMACEUTICAL : Bispecific Antibody "ERY974" Results of Preclinical Stud..
10/12 FOUNDATION MEDICINE : REVOLUTION Medicines Appoints Vincent Miller, M.D. to Boar..
10/12 PTC THERAPEUTICS : RG7916 Increased SMN Protein Production in SUNFISH Clinical T..
10/12 FOUNDATION MEDICINE, INC. (NASDAQ : FMI) Files An 8-K Departure of Directors or ..
10/12 REMINDER : Invitation to Roche's 9 Months Sales 2017 Audio Webcast and Conferenc..
10/11 ROCHE : Printed books
10/11 ROCHE : Feasibility study, advisory service, analysis
10/10 ROCHE : FDA Clears Roche C. difficile Assay for Liat Platform
10/10 CHUGAI PHARMACEUTICAL : Bispecific Antibody 'ERY974' Results of Preclinical Stud..
10/10 ROCHE : s Tecentriq cedes bladder-cancer share to Keytruda in wake of trial misf..
10/07 ROCHE : AMCP Foundation and Genentech Offered Summer Internships in Managed Care..
10/07 ROCHE : gets FDA nod for Zika-screening blood test
10/07 ABBVIE : NICE recommends access to venclyxto for adult leukaemia
10/06 ROCHE : FDA approves Roche cobas Zika as first commercially-available donor scre..
10/06 ABBVIE : NICE recommends access to venclyxto for adult leukaemia
10/06 ROCHE : Aspen welcomes decision to drop price probe
10/06 Aspen and Equity probes halt
10/05 FOUNDATION MEDICINE : Glancy Prongay & Murray Reminds Investors of Looming Deadl..
10/05 TEXAS INSTRUMENTS : Patent Issued for Power Control for Multichannel Signal Proc..
10/05 ROCHE : Aspen welcomes decision to drop price probe
10/05 ROCHE : Aspen welcomes decision to drop price probe
10/04 ROCHE : Trastuzumab Treatment for HER-2-Expressing Tumors Need Not Delay Breast ..
10/03 ROCHE : Genentech - FDA Grants Priority Review for Genentech's Perjeta for Adjuv..
10/03 ROCHE : Secondary school construction work
10/03 ROCHE : Printed books
10/03 ROCHE : launches NAVIFY Tumor Board solution to provide decision support to onco..
10/02 ROCHE : 65-- Intent to Award IAW FAR 8.405-6 Roche COBAS HIV,HBV and HCV reagent..
10/02 GALENA BIOPHARMA : Announces Completion of Enrollment in Two NeuVax Clinical Tri..
09/29 ROCHE : Global Legal Centre Campaign Shows Why Business Chooses England, Wales
09/29 ROCHE : La Roche to Host 5K Race Benefiting Hurricane Relief Student Aid Fund
09/29 GALENA BIOPHARMA : Announces Completion of Enrollment in Two NeuVax (nelipepimut..
09/29 ROCHE : FDA grants Priority Review for Roche’s Perjeta (pertuzumab) for ad..
09/29 ROCHE : FDA Grants Priority Review for Genentech’s Perjeta (Pertuzumab) fo..
09/28 FOUNDATION MEDICINE : New study shows that genomic profiling can help improve tr..
09/28 ABBVIE : Announces Positive Topline Results from Phase 3 Trial Evaluating VENCLE..
09/28 ROCHE : Six-Year-Old to Serve as Honorary Captain for La Roche Soccer Team
09/28 ROCHE : BioLineRx Announces Initiation of Phase 1b/2 Trial for BL-8040 in AML un..
09/28DJROCHE : Gets Switzerland Approval for Multiple Sclerosis Treatment
09/28 ROCHE : OCREVUS (ocrelizumab) approved in Switzerland for primary progressive an..
09/28 EPIZYME, INC. (NASDAQ : EPZM) Files An 8-K Departure of Directors or Certain Off..
09/26 ROCHE : EU green light for Roches Tecentriq
09/26 ROCHE : s Actemra/RoActemra receives new European approval
1  2  3  4  5  6  7  8  9  10Next
Financials ( CHF)
Sales 2017 53 420 M
EBIT 2017 18 236 M
Net income 2017 11 152 M
Debt 2017 9 920 M
Yield 2017 3,60%
P/E ratio 2017 17,77
P/E ratio 2018 16,18
EV / Sales 2017 4,03x
EV / Sales 2018 3,79x
Capitalization 205 B
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 274  CHF
Spread / Average Target 15%
EPS Revisions
Managers
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.215 760
JOHNSON & JOHNSON23.29%377 585
NOVARTIS13.50%226 453
ROCHE HOLDING LTD.5.55%215 760
PFIZER11.58%213 372
MERCK AND COMPANY7.88%173 214